Skip to Content
Merck
  • Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.

Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.

Blood cancer journal (2014-03-25)
O E Olsen, K F Wader, K Misund, T K Våtsveen, T B Rø, A K Mylin, I Turesson, B F Størdal, S H Moen, T Standal, A Waage, A Sundan, T Holien
ABSTRACT

Multiple myeloma is a malignancy of plasma cells predominantly located in the bone marrow. A number of bone morphogenetic proteins (BMPs) induce apoptosis in myeloma cells in vitro, and with this study we add BMP-9 to the list. BMP-9 has been found in human serum at concentrations that inhibit cancer cell growth in vitro. We here show that the level of BMP-9 in serum was elevated in myeloma patients (median 176 pg/ml, range 8-809) compared with healthy controls (median 110 pg/ml, range 8-359). BMP-9 was also present in the bone marrow and was able to induce apoptosis in 4 out of 11 primary myeloma cell samples by signaling through ALK2. BMP-9-induced apoptosis in myeloma cells was associated with c-MYC downregulation. The effects of BMP-9 were counteracted by membrane-bound (CD105) or soluble endoglin present in the bone marrow microenvironment, suggesting a mechanism for how myeloma cells can evade the tumor suppressing activity of BMP-9 in multiple myeloma.

MATERIALS
Product Number
Brand
Product Description

Millipore
MILLIPLEX® Human Angiogenesis/Growth Factor Magnetic Bead Panel - Cancer Multiplex Assay, Angiogenesie Bead-Based Multiplex Assays using the Luminex technology enables the simultaneous analysis of multiple angiogenic biomarkers in human serum, plasma and cell culture samples.